Owing to the synchronous highly expression pattern of Wnt5a in breast cancer, gastric cancer, non-small-cell lung cancer, prostate cancer [22, 29–32], we predict that Wnt5a and ROR2 may act as co-effector in certain specific tumors. This evidence concerns the gene ROR2 and non-small cell lung carcinoma.